Why Combine HCG With TRT? Fertility and Testicular Function

Men often ask about hCG with TRT because testosterone replacement therapy, while effective for symptoms of low testosterone, can suppress the body’s own sperm-producing signals. Adding human chorionic gonadotropin (hCG) is a strategy some clinicians use to help preserve intratesticular testosterone, testicular size, and sperm production during therapy. This article explains the underlying biology, what the primary research actually shows, and the important regulatory and safety context, all as educational information rather than medical advice.

How does TRT affect fertility and the testes?

Your testes make testosterone and sperm under instruction from the brain. The hypothalamus releases GnRH, the pituitary releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and those gonadotropins drive Leydig cells (testosterone) and Sertoli cells (sperm support). When you add testosterone from outside the body, the brain senses plenty of hormone and dials the system down through negative feedback, reducing LH and FSH (Crosnoe et al., Transl Androl Urol).

That shutdown matters because sperm production depends on a very high testosterone concentration inside the testis, not the level in your blood. In a randomized study of 29 healthy men, testosterone enanthate 200 mg/week plus placebo for three weeks suppressed intratesticular testosterone by 94% (from 1234 to 72 nmol/L), while serum LH and FSH fell to roughly 5% and 3% of baseline; the authors noted serum testosterone was only about 1.2% of ITT (Coviello et al., JCEM 2005). Supporting the mechanism, a review of testosterone- and steroid-induced infertility notes that a rat study found an approximately 80% drop in ITT caused dramatic spermatogenic impairment; that figure comes from an animal model and is cited to illustrate how dependent sperm production is on ITT, not as a validated human threshold (clinician’s guide, PMC12112917).

The visible consequence is testicular shrinkage. The same review reports testicular atrophy of about 16.5% to 30% with exogenous testosterone or anabolic steroids, since the seminiferous tubules (which make sperm) account for roughly two-thirds of testicular volume. Studies of testosterone used at contraceptive doses show how profound the effect can be: in the WHO contraceptive trial, weekly testosterone enanthate 200 mg rendered 157 of 271 men azoospermic, a cumulative 65% by six months (WHO Task Force, 1990). Those are male-contraception data and should not be read as the exact rate every TRT patient will experience, but they illustrate that testosterone alone can strongly suppress sperm production. If preserving fertility matters to you, this trade-off is worth discussing before starting therapy; our overview of enclomiphene vs TRT covers a different fertility-sparing approach.

What does hCG do, and why pair it with testosterone?

hCG closely mimics LH. The two hormones share an identical alpha subunit and bind the same Leydig-cell receptor (LHCGR), and their beta subunits are closely homologous; hCG’s beta subunit carries an extra C-terminal peptide that gives it a substantially longer circulating half-life than LH (Casarini et al., Endocrine Reviews 2018). Because TRT silences the pituitary’s LH signal, supplying hCG can step in as an LH-like stimulus to keep Leydig cells producing testosterone right where sperm are made.

The clearest mechanistic evidence comes from the Coviello study above. In those 29 healthy men on testosterone enanthate, adding low-dose hCG every other day maintained ITT in a dose-dependent way over three weeks: ITT sat about 25% below baseline at 125 IU, about 7% below at 250 IU, and about 26% above baseline at 500 IU every other day (Coviello et al., JCEM 2005). This is a short-term, surrogate-marker study in men with normal reproductive physiology, so it shows the hormonal mechanism rather than long-term fertility outcomes.

Scenario (population)	Effect on intratesticular testosterone
Testosterone enanthate 200 mg/wk + placebo, 3 wk (29 healthy men)	94% below baseline
+ hCG 125 IU every other day (same study)	~25% below baseline
+ hCG 250 IU every other day (same study)	~7% below baseline
+ hCG 500 IU every other day (same study)	~26% above baseline

Source: Coviello et al., JCEM 2005 (n=29 healthy men, 3-week study). Figures apply only to this population and duration.

Does hCG actually help preserve sperm production on TRT?

The most-cited clinical evidence is a small retrospective series. In 26 hypogonadal men (mean age 35.9) given hCG 500 IU intramuscularly every other day alongside TRT, with a mean follow-up of 6.2 months, no patient became azoospermic, semen parameters were maintained for more than a year, and 9 of the 26 contributed to a pregnancy (Hsieh et al., J Urol 2013). This is encouraging and consistent with the mechanism, but as a small retrospective study with short follow-up it is suggestive rather than definitive proof, and it does not guarantee any individual’s outcome.

It is also worth knowing what happens without an LH-like stimulus. After men stop hormonal suppression, sperm production tends to recover on a predictable timeline: an integrated analysis of 1,549 healthy eugonadal men across 30 contraception studies found a median time to a sperm concentration of 20 million/mL of 3.4 months, with 67% recovering by 6 months, 90% by 12 months, and 100% by 24 months (Liu et al., Lancet 2006). Those recovery figures come from men stopping suppression in contraception trials, not from TRT patients, and they are not a promise for any one person. The appeal of hCG is the possibility of maintaining function during therapy rather than relying on recovery afterward.

Is hCG with TRT FDA-approved?

This is where careful framing matters. FDA-approved hCG products do exist (for example, Pregnyl, Novarel, and Ovidrel), but the approved indication for men is “selected cases of hypogonadotropic hypogonadism (secondary to a pituitary deficiency) in males,” along with prepubertal cryptorchidism; the label contains no indication for use alongside testosterone replacement or for preserving fertility during TRT (Pregnyl prescribing information, DailyMed). In other words, combining hCG with TRT for fertility or testicular support is an off-label, provider-determined use.

The hCG offered through Revive is compounded by a state-licensed compounding pharmacy under Section 503A and is not FDA-approved; the FDA has not evaluated it for safety, quality, or efficacy. The regulatory backdrop is also worth understanding: as of March 23, 2020, hCG transitioned to being regulated as a biological product under the PHS Act, which changed the compounding pathway and the available supply (FDA Notice to Compounders, 2020). After that change, access to compounded hCG fell sharply: in a survey of compounding pharmacies, only 5 of 75 still compounded hCG, and 6 of the 8 that stopped cited the 2020 mandate, while FDA-approved brand hCG remained available at higher cost (PMC10083688). Cost figures like these are general US-market context, not Revive pricing. Because the sourcing and regulatory status of any specific hCG product can vary, ask your provider exactly what product they are prescribing, how it is compounded or approved, and how it is regulated.

What should I know about the testosterone side of the regimen?

Testosterone is a DEA Schedule III controlled substance; anabolic steroids pharmacologically related to testosterone were placed in Schedule III by the Anabolic Steroids Control Act of 1990, and the DEA’s schedules list testosterone products (for example, Depo-Testosterone) among Schedule III substances (DEA Controlled Substance Schedules). It requires a valid prescription and a real diagnosis. The AUA recommends diagnosing testosterone deficiency using both symptoms and two separate early-morning total testosterone measurements, with under 300 ng/dL as a reasonable cutoff (AUA Guideline, 2018). For more on that threshold, see our note on whether testosterone is a controlled substance and the TRT dosage guide.

Ongoing monitoring typically includes hemoglobin/hematocrit, PSA, and blood pressure. On February 28, 2025, the FDA issued class-wide labeling changes for testosterone products: it removed the boxed cardiovascular warning following the TRAVERSE trial, retained the age-related “Limitation of Use,” and added an updated blood-pressure warning based on required monitoring studies (FDA, 2025). FDA-approved testosterone products exist, and a licensed provider will determine what is appropriate for you.

Frequently asked questions

Does TRT cause infertility?

Testosterone from outside the body suppresses pituitary LH and FSH, which lowers intratesticular testosterone and can impair sperm production; in a randomized study of healthy men, testosterone alone suppressed intratesticular testosterone by 94% over three weeks (Coviello, JCEM 2005). Studies of testosterone at contraceptive doses show high rates of suppressed sperm production. The degree and reversibility vary between individuals, and this is a key topic to raise with a provider before starting therapy. This is educational information, not medical advice.

How does hCG help during testosterone therapy?

hCG acts on the same Leydig-cell receptor as LH and has a longer circulating half-life, so it can supply an LH-like stimulus that TRT otherwise suppresses. In one short study of healthy men, low-dose hCG every other day maintained intratesticular testosterone in a dose-dependent way (Coviello, JCEM 2005), and a small retrospective series of men on TRT plus hCG saw no azoospermia (Hsieh, J Urol 2013). Benefits are not guaranteed and individual results vary.

Is using hCG with TRT FDA-approved?

No. FDA-approved hCG products exist, but they are approved for hypogonadotropic hypogonadism from pituitary deficiency in males and for prepubertal cryptorchidism, not for fertility preservation during testosterone therapy (Pregnyl label, DailyMed). Combining hCG with TRT for testicular or fertility support is off-label and provider-determined. The hCG offered through Revive is compounded under Section 503A and is not FDA-approved; the FDA has not evaluated it for safety, quality, or efficacy. hCG was reclassified as a biologic in 2020, which changed the compounding pathway and supply, so confirm with your provider exactly what product you are receiving and how it is regulated.

Will sperm production recover if I stop TRT instead of using hCG?

Often, but not always, and on a variable timeline. An integrated analysis of healthy men in contraception studies found a median recovery to 20 million/mL of 3.4 months, with 90% by 12 months and 100% by 24 months after stopping suppression (Liu, Lancet 2006). Those figures come from contraception trials, not TRT patients, and do not guarantee recovery for any individual. Some clinicians use hCG to try to maintain function during therapy rather than rely on later recovery.

What dose of hCG is used with TRT?

There is no single approved dose for this off-label use. The published studies used 500 IU every other day (Hsieh, J Urol 2013), and the dose-finding study tested 125, 250, and 500 IU every other day in healthy men (Coviello, JCEM 2005). Any regimen is determined by a licensed provider based on your evaluation and monitoring; do not self-dose. This article is educational and not a dosing recommendation.

Is hCG the same as Revive’s other compounded therapies?

Like other compounded products such as NAD+, sermorelin, and enclomiphene, the hCG offered through Revive is compounded by a state-licensed pharmacy under Section 503A and is not FDA-approved; the FDA has not evaluated it for safety, quality, or efficacy. The regulatory pathway does differ in one respect: hCG was reclassified as a biologic in 2020, which sharply reduced compounded availability, and separate FDA-approved hCG products (such as Pregnyl, Novarel, and Ovidrel) also exist for certain indications. Because sourcing and regulatory status can differ, ask your provider exactly what hCG product is being prescribed and how it is regulated.